- Anthem Biosciences Ltd debuted in the secondary market with a 27% premium over its IPO price
- The shares were listed at Rs 723.05 on the NSE
- The shares were listed at Rs 723.1 on the BSE
Anthem Biosciences Ltd. made a stellar debut in the secondary market with a premium of 27% over its IPO price. The scrip was listed at Rs 723.05 apiece on the NSE and Rs 723.1 on the BSE. The issue price was Rs 570.
The IPO was a book-building issue of Rs 3,395 crore and entirely an offer for sale from its promoters, investors and other selling shareholders.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Since this IPO was fully an OFS, the contract research, development and manufacturing company will not receive any funds, which will be directed to the selling shareholders.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Anthem Biosciences IPO received a solid response, particularly from Qualified Institutional Buyers (QIBs) who subscribed 182.65 times, followed by non-institutional investors (NIIs) at 42.36 times.
Retail investors' quota had a subscription rate of 5.64 times. By the end of the third day, the Anthem Biosciences IPO subscription status stood at 63.86 times.
The initial share sale received bids for 281 crore shares against 4.4 crore shares on offer.
JM Financial was the sole domestic merchant banker to the deal.
Anthem Biosciences is an innovation-driven and technology-focused contract research, development, and manufacturing organisation (CRDMO) with integrated operations encompassing drug discovery, development, and manufacturing processes.
The company serves customers, including emerging biotech firms and large pharmaceutical companies on a global scale. It manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
Listed peers of Anthem Biosciences include Sai Life Sciences Ltd, Syngene International Ltd., Suven Life Sciences Ltd., and Divi's Laboratories Ltd.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
